20- O- (Nalpha- (4- (3- O- methylfucopyranosyloxy)phenylaminothiocarbonyl)histidylvalyl)camptothecin
BAY-383441 is the (20S,HCl)-isomer; structure in first source
Also Known As:
20-O-(Nalpha-(4-(3-O-methylfucopyranosyloxy)phenylaminothiocarbonyl)histidylvalyl)camptothecin hydrochloride; BAY 38-3441; BAY 383441; BAY 56-3722; BAY-38-3441; BAY-383441; BAY383441
Networked: 3
relevant articles (0 outcomes,
3 trials/studies)
Bio-Agent Context: Research Results
Experts
| 1. | Gelderblom, Hans:
1 article
(06/2012)
|
| 2. | Slingerland, Marije:
1 article
(06/2012)
|
| 3. | Bangash, Naeema:
1 article
(10/2005)
|
| 4. | Batist, Gerald:
1 article
(10/2005)
|
| 5. | Chen, Eric X:
1 article
(10/2005)
|
| 6. | Lathia, Chetan:
1 article
(10/2005)
|
| 7. | Maclean, Martha:
1 article
(10/2005)
|
| 8. | McIntosh, Lynn:
1 article
(10/2005)
|
| 9. | Miller, Wilson H:
1 article
(10/2005)
|
| 10. | Oza, Amit M:
1 article
(10/2005)
|
Related Diseases
| 1. | Neoplasms (Cancer)
08/01/2004
- " A total of 81 patients with advanced solid tumors were treated with BAY 38-3441 either at doses of 20, 40, 67, 100, 140, 210, 315, 470 and 600 mg/m2/day for 1 day every 3 weeks (single-dose schedule), or at doses of 126, 189, 246, 320 and 416 mg/m2/day once daily for three consecutive days every 3 weeks (3-day schedule). " 10/01/2005
- " Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies." 08/01/2004
- " A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors." 10/01/2005
- " Bay 38-3441 is a camptothecin glycoconjugate which stabilizes the active lactone form of camptothecin and allows selective uptake into tumor cells. "
|
| 2. | Colorectal Neoplasms (Colorectal Cancer)
|
| 3. | Agranulocytosis (Granulocytopenia)
|
|
Related Drugs and Biologics